Macomics

back to Directory

Macomics

Macomics logo

Founded
2018

Macomics harnesses world-leading expertise in macrophage biology, which in combination with the company’s proprietary technology will provide insights into TAMs and the tumour microenvironment, and lead to therapeutic discoveries that will increase the body’s immune defence against tumours across various cancers.

Posts Mentioning This Company

Macomics Unveils ENIGMAC™ Discovery Platform at AACR for Target Validation in Macrophage Therapies

Macomics Ltd, a frontrunner in macrophage drug discovery, recently showcased its innovative ENIGMAC™ macrophage drug discovery platform at the American Association for Cancer Research's Annual Meeting (AACR 2023). The company aims to harness the potential of macrophage-based approaches to create novel precision medicines targeting disease-specific macrophage biology.

R&D Platform

ENIGMAC™ incorporates novel assay systems, unique genome editing methods, supported by multi-omics bioinformatics analyses. We use a human Induced Pluripotent Stem Cell (iPSC) line that yields macrophages phenotypically and functionally very similar to HUMAN monocyte-derived macrophages (MDM). By employing this iPSC system we can produce millions of macrophages per week, which allows multiple high throughput assays to support target validation and drug discovery. In addition, we have developed a suite of technologies to allow fast and reliable gene editing of macrophages. Our proprietary toolbox allows us to perform gene Knock In (KI), Knock Out (KO) and Knock Down (KD) with high efficiency both at iPSC and macrophage level while maintaining expression/silencing during macrophage differentiation. KD can be performed using a pooled approach that enables screening by flow cytometry-based phenotypes at large scale.